Brand (Generic) Name |
Sections Modified |
Summary of Changes to Contraindications
and Warnings |
Cipro I.V. (ciprofloxacin)
for Intravenous Infusion
(click product name to read prescribing information) |
CONTRAINDICATIONS
WARNINGS
PRECAUTIONS
- Information for Patients
- Drug Interactions
|
CONTRAINDICATIONS
Ciprofloxacin is
contraindicated in persons with a history of hypersensitivity to
ciprofloxacin, any member of the quinolone class of antimicrobial
agents, or any of the product components.
Concomitant administration with
tizanidine is contraindicated.
WARNINGS
Ciprofloxacin is an inhibitor of the hepatic CYP1A2 enzyme
pathway. Coadministration of ciprofloxacin and other drugs
primarily metabolized by CYP1A2 (e.g. theophylline,
methylxanthines, tizanidine) results in increased plasma
concentrations of the coadministered drug and could lead to
clinically significant pharmacodynamic side effects of the
coadministered drug. |
Cipro (ciprofloxacin
hydrochloride) Tablets
Cipro (ciprofloxacin)
Oral Suspension
(click product name to read prescribing information) |
CONTRAINDICATIONS
WARNINGS
PRECAUTIONS
- Information for Patients
- Drug interactions
PATIENT PACKAGE INSERT |
CONTRAINDICATIONS
Ciprofloxacin is
contraindicated in persons with a history of hypersensitivity to
ciprofloxacin, any member of the quinolone class of antimicrobial
agents, or any of the product components.
Concomitant administration with
tizanidine is contraindicated.
WARNINGS
Ciprofloxacin is an inhibitor of the hepatic CYP1A2 enzyme
pathway. Coadministration of ciprofloxacin and other drugs
primarily metabolized by CYP1A2 (e.g. theophylline,
methylxanthines, tizanidine) results in increased plasma
concentrations of the coadministered drug and could lead to
clinically significant pharmacodynamic side effects of the
coadministered drug. |
|
|
|
Cipro XR (ciprofloxacin
extended-release tablets)
(click product name to read prescribing information) |
CONTRAINDICATIONS
WARNINGS
PRECAUTIONS
- Information for Patients
- Drug Interactions
PATIENT PACKAGE INSERT |
CONTRAINDICATIONS
Ciprofloxacin is
contraindicated in persons with a history of hypersensitivity to
ciprofloxacin, any member of the quinolone class of antimicrobial
agents, or any of the product components.
Concomitant administration with
tizanidine is contraindicated.
WARNINGS
Ciprofloxacin is an inhibitor of the hepatic CYP1A2 enzyme
pathway. Coadministration of ciprofloxacin and other drugs
primarily metabolized by CYP1A2 (e.g. theophylline,
methylxanthines, tizanidine) results in increased plasma
concentrations of the coadministered drug and could lead to
clinically significant pharmacodynamic side effects of the
coadministered drug. |
|
|
|
DDAVP
Injection (desmopressin
acetate)
(click product name to read prescribing information) |
CONTRAINDICATIONS
PRECAUTIONS
|
CONTRAINDICATIONS
. . . DDAVP is contraindicated in patients with moderate to
severe renal impairment (defined as a
creatinine clearance below 50ml/min). |
|
|
|
DDAVP Nasal Spray (desmopressin
acetate)
(click product name to read prescribing information) |
CONTRAINDICATIONS
PRECAUTIONS
|
CONTRAINDICATIONS
. . . DDAVP is contraindicated in patients with
moderate to severe renal impairment (defined as a
creatinine clearance below 50ml/min). |
|
|
|
DDAVP Rhinal Tube (desmopressin
acetate) (click product name to read prescribing information)
|
CONTRAINDICATIONS
PRECAUTIONS
|
CONTRAINDICATIONS
. . . DDAVP is contraindicated in patients with moderate to
severe renal impairment (defined as a
creatinine clearance below 50ml/min). |
|
|
|
DDAVP Tablets
(desmopressin acetate) (click product name to read prescribing information)
|
CONTRAINDICATIONS
PRECAUTIONS
|
CONTRAINDICATIONS
. . . DDAVP is contraindicated in patients with moderate to
severe renal impairment (defined as a
creatinine clearance below 50ml/min). |
|
|
|
Norvir (ritonavir
capsules) Soft Gelatin & (ritonavir oral solution)
(click product name to read prescribing information) |
CONTRAINDICATIONS
WARNINGS
PRECAUTIONS
- Immune Reconstitution Syndrome
- Information for Patients
- Drug Interactions
- Table 5: Drugs That Should Not
Be Co-administered with Norvir
- Table 6: Established
and Other Potentially Significant Drug Interactions.....
PATIENT PACKAGE INSERT |
CONTRAINDICATIONS
.....Voriconazole is an exception in
that coadministration of Norvir and Voriconazole results in a
significant decrease in plasma concentrations of Voriconazole.
WARNINGS
Particular caution should be
used when prescribing PDE5 inhibitors for erectile dysfunction (eg,
sildenafil, tadalafil, or vardenafil) for patients receiving
protease inhibitors, including Norvir..... |
MedWatch
Home | Safety Information | Submit
Report | How to Report | Download
Forms | Join the E-list | Comments
Back to Summary Page
Brand (Generic) Name
|
Sections Modified |
Summary of Changes to Contraindications and Warnings
|
Strattera (atomoxetine
hydrochloride) Capsules
(click product name to read prescribing information)
|
BOXED WARNING
WARNINGS
PRECAUTIONS
- Information for Patients
- Initial Paragraph
- Suicide Risk
- Pediatric Use
MEDICATION GUIDE
|
BOXED WARNING
Strattera (atomoxetine) increased
the risk of suicidal ideation in short-term studies in children
or adolescents with Attention-Deficit/Hyperactivity Disorder
(ADHD). Anyone considering the use of Strattera in a child or
adolescent must balance this risk with the clinical need.
Patients who are started on therapy should be monitored closely
for suicidality (suicidal thinking and behavior), clinical
worsening, or unusual changes in behavior. Families and
caregivers should be advised of the need for close observation
and communication with the prescriber. Strattera is approved for
ADHD in pediatric and adult patients. Strattera is not approved
for major depressive disorder.....
WARNINGS
Suicidal Ideation
.....All pediatric patients being
treated with Strattera should be monitored closely for
suicidality, clinical worsening, and unusual changes in
behavior, especially during the initial few months of a course
of drug therapy, or at times of dose changes. Such monitoring
would generally include at least weekly face-to-face contact
with patients or their family members or caregivers during the
first 4 weeks of treatment, then every other week visits for the
next 4 weeks, then at 12 weeks, and as clinically indicated
beyond 12 weeks. Additional contact by telephone may be
appropriate between face-to-face visits.
.....Families and caregivers
of pediatric patients being treated with Strattera should be
alerted about the need to monitor patients for the emergence of
agitation, irritability, unusual changes in behavior, and the
other symptoms described above, as well as the emergence of
suicidality, and to report such symptoms immediately to
healthcare providers.....
Screening Patients for Bipolar
Disorder
In general, particular care
should be taken in treating ADHD in patients with comorbid
bipolar disorder because of concern for possible induction of a
mixed/manic episode in patients at risk for bipolar disorder.
Whether any of the symptoms described above represent such a
conversion is unknown.....
For additional details, see MedWatch 9/29/05 Safety Alert.
|
|
|
|
Tracleer (bosentan) Film-coated Tablets
(click product name to read prescribing information)
|
BOXED WARNING
WARNINGS
PRECAUTIONS
- Pulmonary Veno-Occlusive
Disease (PVOD)
- Drug Interactions
ADVERSE REACTIONS
- Post-Marketing Experience
- Unexplained
Hepatic Cirrhosis
MEDICATION GUIDE |
BOXED WARNING
.....In the
post-marketing period, in the setting of close monitoring, rare
cases of unexplained hepatic cirrhosis were reported after
prolonged (> 12 months) therapy with Tracleer in patients
with multiple co-morbidities and drug therapies. The
contribution of Tracleer in these cases could not be excluded.
In at least one case
the initial presentation (after > 20 months of treatment)
included pronounced elevations in aminotransferases and
bilirubin levels accompanied by nonspecific symptoms, all of
which resolved slowly over time after discontinuation of
Tracleer. This case reinforces the importance of strict
adherence to the monthly monitoring schedule for the duration of
treatment and the treatment algorithm, which includes stopping
Tracleer with a rise of aminotransferases accompanied by signs
or symptoms of liver dysfunction.....
WARNINGS
.....Elevations of AST
and/or ALT associated with bosentan are dose-dependent, occur
both early and late in treatment, usually progress slowly, are
typically asymptomatic, and usually have been reversible after
treatment interruption or cessation. Aminotransferase elevations
also may reverse spontaneously while continuing treatment with
Tracleer.....
|
|
|
|
Xyrem (sodium oxybate) Oral Solution
(click product name to read prescribing information)
|
BOXED WARNING
WARNINGS
PRECAUTIONS
-
Incontinence
-
Sodium Intake
-
Information for Patients
|
BOXED WARNING
Xyrem
is available through the Xyrem Success Program, using a
centralized pharmacy 1- 866-XYREM88
(1-866-997-3688). The Success
Program provides educational materials to the
prescriber and the patient explaining the risks and proper use
of sodium oxybate, and the required
prescription form. Once it is documented that the patient has
read and/or understood the
materials, the drug will be shipped to the patient. The Xyrem
Success Program also recommends
patient follow-up every 3 months. Physicians are expected
to report all serious adverse events to the manufacturer.
WARNINGS
In clinical trials, 3.2% of
patients treated with sodium oxybate reported depressive
symptoms. In the majority of cases, no change in sodium oxybate
treatment was required. Four patients (<1%) discontinued
because of depressive symptoms. In the controlled clinical trial
where patients were randomized to fixed doses of 3, 6, 9 g/night
or placebo, there was a single event of depression at the 3
g/night dose. In Trial 3, where patients were titrated from an
initial 4.5 g/night starting dose, the incidence of depression
was 1 (1.7%), 1 (1.5%), 2 (3.2%), and 2 (3.6%) for the placebo,
4.5g, 6 g, and 9 g/night doses respectively.
|
MedWatch
Home | Safety Information | Submit
Report | How to Report | Download
Forms | Join the E-list | Comments
Back to Summary Page
Brand (Generic) Name |
Sections Modified |
Summary of Changes to Contraindications
and Warnings |
Agenerase (amprenavir)
Oral Solution
(click product name to read prescribing information) |
WARNINGS
PRECAUTIONS
- Immune Reconstitution Syndrome
- Drug Interactions
- Table 8
- Other Agents
- Antidepressant
- Inhaled/nasal steroid
|
A drug interaction
study in healthy subjects has shown that ritonavir significantly
increases plasma fluticasone propionate exposures, resulting in
significantly decreased serum cortisol concentrations.
Concomitant use of Agenerase with ritonavir and fluticasone
propionate is expected to produce the same effects. Systemic
corticosteroid effects including Cushing's syndrome and
adrenal suppression have been reported during postmarketing use
in patients receiving ritonavir and inhaled or intranasally
administered fluticasone propionate. Therefore, coadministration
of fluticasone propionate and Agenerase/ritonavir is not
recommended unless the potential benefit to the patient
outweighs the risk of systemic corticosteroid side effects. |
|
|
|
Aranesp (darbepoetin alfa) for Injection
(click product name to read prescribing information) |
WARNINGS
ADVERSE REACTIONS
|
Cases of pure red cell aplasia (PRCA)
and of severe anemia, with or without other cytopenias,
associated with neutralizing antibodies to erythropoietin have
been reported in patients treated with Aranesp. This has been
reported predominantly in patients with CRF receiving Aranesp by
subcutaneous administration. Any patient who develops a sudden
loss of response to Aranesp, accompanied by severe anemia and
low reticulocyte count, should be evaluated for the etiology of
loss of effect, including the presence of neutralizing
antibodies to erythropoietin. If anti-erythropoietin
antibody-associated anemia is suspected, withhold Aranesp and
other erythropoietic proteins. Contact Amgen (1-800-77AMGEN) to
perform assays for binding and neutralizing antibodies. Aranesp
should be permanently discontinued in patients with
antibody-mediated anemia. Patients should not be switched to
other erythropoietic proteins as antibodies may cross-react.
For additional details, see MedWatch 12/01/05 Safety Alert. |
|
|
|
Effexor
XR (venlafaxine hydrochloride) Extended-Release Capsules
(click product name to read prescribing information)
|
WARNINGS
PRECAUTIONS
- General
- Insomina/Nervousness
- Changes in Weight
- Changes in Appetite
- Activation of Mania/Hypomania
- Seizures
- Use in Patients with Concomitant
Illness
- Geriatric Use
ADVERSE REACTIONS
-
Adverse Findings Observed
in Short-Term, Placebo-Controlled Studies with Effexor XR
-
Adverse
Events Occurring at an Incidence of 2% or More Among Effexor
XR Treated Patients
-
Panic Disorder
-
Vital Sign
Changes
-
Laboratory Changes
-
Other Adverse Events Observed During the
Premarketing Evaluation of Effexor and Effexor XR
-
Initial Section
-
Nervous System
|
.....Among patients treated
with 75 to 225 mg/day of Effexor XR in premarketing panic
disorder studies, 0.9% (9/973) experienced sustained
hypertension.....
|
|
|
|
Mevacor (lovastatin) Tablets
(click product name to read prescribing information) |
WARNINGS
- Myopathy/Rhabdomyolysis
- Table VI
PRECAUTIONS
|
Myopathy/Rhabdomyolysis
Lovastatin, like other
inhibitors of HMG-CoA reductase, occasionally causes myopathy
manifested as muscle pain, tenderness or weakness with
creatine kinase (CK) above ten times the upper limit of normal
(ULN). Myopathy sometimes takes the form of rhabdomyolysis
with or without acute renal failure secondary to myoglobinuria,
and rare fatalities have occurred. The risk of myopathy is
increased by high levels of HMG-CoA reductase inhibitory
activity in plasma.....
Table VI
New Table added entitled "Drug
Interactions Associated with Increased Risk of
Myopathy/Rhabdomyolysis." (See prescribing information
for table). |
|
|
|
NovoSeven Coagulation Factor VIIa
(Recombinant)
(click product name to read prescribing information) |
WARNINGS
ADVERSE REACTIONS
- Post-Marketing Experience
|
The extent of the
risk of thrombotic adverse events after treatment with NovoSeven
in patients with hemophilia and inhibitors is not known, but is
considered to be low. Patients with disseminated intravascular
coagulation (DIC), advanced atherosclerotic disease, crush
injury, septicemia, or concomitant treatment with aPCCs/PCCs
(activated or nonactivated prothrombin complex concentrates) may
have an increased risk of developing thrombotic events due to
circulating TF or predisposing coagulopathy.
The extent of the
risk of arterial and venous thromboembolic adverse events after
treatment with NovoSeven in patients without hemophilia is also
not known. A clinical study in elderly non-hemophilia
intracerebral hemorrhage patients indicated a potential
increased risk of arterial thromboembolic adverse events with
use of NovoSeven, including myocardial ischemia, myocardial
infarction, cerebral ischemia and/or infarction.
For additional details, see MedWatch 12/01/05 Safety Alert. |
|
|
|
Ortho Evra (norelgestromin
/ethinyl estradiol transdermal system)
(click product name to read prescribing information) |
WARNINGS
- Pharmacokinetic Profile
- .....There is
limited epidemiologic data available to determine whether
safety with the transdermal route of administration is
different than the oral route.....
PATIENT PACKAGE INSERT |
The
pharmacokinetic (PK) profile for the Ortho Evra patch is
different from the PK profile for oral contraceptives in that it
has higher steady state concentrations and lower peak
concentrations. AUC and average concentration at steady state
for ethinyl estradiol (EE) are approximately 60% higher in women
using Ortho Evra compared with women using an oral contraceptive
containing EE 35 µg. In contrast, peak concentrations for EE
are approximately 25% lower in women using Ortho Evra.
Inter-subject variability results in increased exposure to EE in
some women using either Ortho Evra or oral contraceptives..... |
|
|
|
Tarceva (erlotinib) Tablets
(click product name to read prescribing information)
|
WARNINGS
|
There
have been infrequent reports of serious Interstitial Lung
Disease (ILD)-like events, including fatalities, in patients
receiving Tarceva for treatment of NSCLC, pancreatic cancer or
other advanced solid tumors. In the randomized single-agent
NSCLC study, the incidence of ILD-like events (0.8%) was the
same in both the placebo and Tarceva groups. In the
pancreatic cancer study - in combination with gemcitabine, the
incidence of ILD-like events was 2.5% in the Tarceva plus
gemcitabine group vs. 0.4% in the placebo plus gemcitabine
group.
The overall
incidence of ILD-like events in approximately 4900 Tarceva-treated
patients from all studies (including uncontrolled studies and
studies with concurrent chemotherapy) was approximately 0.7%..... |
MedWatch
Home | Safety Information | Submit
Report | How to Report | Download
Forms | Join the E-list | Comments
Back to Summary Page
Brand
(Generic) Name |
Sections Modified |
Amaryl
(glimepiride tablets)
(click product name to read prescribing information) |
PRECAUTIONS
ADVERSE REACTIONS |
|
|
Aredia (pamidronate
disodium for injection) for Intravenous Infusion
(click product name to read prescribing information) |
PRECAUTIONS |
|
|
Avelox (moxifloxacin
hydrochloride) Tablets
Avelox I.V. (moxifloxacin
hydrochloride in sodium chloride injection)
(click product name to read prescribing information)
|
PRECAUTIONS
-
Information for Patients
- That phototoxicity has been reported in
patients receiving certain quinolones,
and infrequently moxifloxacin.....
-
Pregnancy: Teratogenic
Effects. Pregnancy Category C:
ADVERSE REACTIONS
-
Initial Paragraph
-
Body as a Whole
-
Cardiovascular
- Digestive
-
Hemic and Lymphatic
-
Nervous System
- Insomnia
- Nervousness
- Vertigo
- Somnolence
- Anxiety
- Tremor
-
Additional Clinically Relevant Rare
Events.....
- Anemia
- Hypertension
- Kidney Function Abnormal
- Leg Pain
- Paraesthesia
-
Post-Marketing Adverse Event Reports
|
|
|
Bicillin C-R (penicillin G benzathine and penicillin G procaine
injectable suspension) Disposable Syringe 4 mL for deep IM
injection only
(click product name to read prescribing information) |
PRECAUTIONS |
|
|
Bicillin C-R (penicillin G benzathine and penicillin G procaine
injectable suspension) Tubex 1 mL and 2 mL
for deep IM injection only
(click product name to read prescribing information) |
PRECAUTIONS |
|
|
Bicillin C-R 900/300 (penicillin G benzathine and penicillin G
procaine injectable suspension) Tubex 2 mL for deep IM Injection
only
(click product name to read prescribing information) |
PRECAUTIONS |
|
|
Bicillin L-A (penicillin G benzathine
injectable suspension) Disposable Syringe for deep IM injection
only
(click product name to read prescribing information) |
PRECAUTIONS |
|
|
Bicillin L-A (penicillin G benzathine
injectable suspension) Tubex 1 mL and 2 mL for deep IM injection
only
(click product name to read prescribing information) |
PRECAUTIONS |
|
|
Derma-Smoothe/FS
(fluocinolone
acetonide) Topical Oil, 0.01%
(click product name to read prescribing information) |
PRECAUTIONS
-
General
- .....One
peanut sensitive child experienced a flare of his atopic
dermatitis after 5 days of twice daily treatment with
Derma-Smoothe/FS.
- .....Physicians should
use caution in prescribing Derma-Smoothe/FS for peanut-sensitive individuals.
ADVERSE REACTIONS
-
Initial Paragraph
- ....One
peanut sensitive child experienced a flare of his atopic
dermatitis after 5 days of twice daily treatment with
Derma-Smoothe/FS.
-
A post marketing
(open-label) safety study was conducted in 58 children to
evaluate the local safety of Derma-Smoothe/FS when applied
twice daily for 4 weeks to the face in children (2 to 12
years) with moderate to severe atopic dermatitis.
- Table:
Incidence of Adverse Events (%)
|
|
|
Effexor
XR (venlafaxine hydrochloride) Extended-Release Capsules
(click product name to read prescribing information)
|
PRECAUTIONS
-
General
-
Changes in Weight
-
Changes in Height
-
Changes in Appetite
|
|
|
Fosamax
(alendronate sodium) Tablets and Oral Solution
(click product name to read prescribing information) |
PRECAUTIONS
ADVERSE REACTIONS
-
Post-Marketing Experience
- Localized Osteonecrosis of
the Jaw.....
PATIENT PACKAGE INSERT |
|
|
Fosamax
Plus D (alendronate sodium/cholecalciferol) Tablets
(click product name to read prescribing information) |
PRECAUTIONS
ADVERSE REACTIONS
-
Post-Marketing Experience
- Localized Osteonecrosis of
the Jaw.....
PATIENT PACKAGE INSERT |
|
|
Hiprex (methenamine
hippurate tablets, USP)
(click product name to read prescribing information)
|
SYSTEMIC ANTIBACTERIAL DRUG PRODUCTS STATEMENT to reduce
the development of drug-resistant bacteria. PRECAUTIONS |
|
|
Ketek (telithromycin) Tablets
(click product name to read prescribing information) |
PRECAUTIONS
-
General
- Information for Patients
ADVERSE REACTIONS
-
Post-Marketing Adverse
Event Reports
-
Allergic
- Face Edema
- Rare Reports of Severe Allergic
Reactions, including Angioedema and Anaphylaxis
-
Cardiovascular
- Atrial Arrhythmias
- Palpitations
-
Gastrointestinal System
-
Liver and Biliary System
-
Musculoskeletal
- Muscle Cramps
- Exacerbation of Myasthenia Gravis
-
Nervous System
|
|
|
Kytril (granisetron
hydrochloride)
Injection
(click product name to read prescribing information)
|
PRECAUTIONS
-
Drug Interactions
- Ketoconazole
- Phenobarbital
|
|
|
Kytril (granisetron
hydrochloride) Tablets and Oral Solution
(click product name to read prescribing information) |
PRECAUTIONS
- Initial
Paragraph
-
Drug Interactions
- Ketoconazole
- Phenobarbital
|
|
|
Lamisil (terbinafine
hydrochloride tablets)
(click product name to read prescribing information)
|
PRECAUTIONS
ADVERSE REACTIONS
- Psoriasiform Eruptions or
Exacerbation of Psoriasis
- Acute Generalized
Exanthematous Pustulosis
|
|
|
Lexiva (fosamprenavir
calcium) Tablets
(click product name to read prescribing information)
|
PRECAUTIONS
-
Table 13
-
Histamine
H2-receptor Antagonists
- Cimetidine,
Famotidine, Nizatidine, Ranitidine
-
Proton Pump
Inhibitors
- Esomeprazole,
Lansoprazole, Omeprazole, Pantoprazole, Rabeprazole
|
|
|
Neutrexin
(trimetrexate glucuronate for injection)
(click product name to read prescribing information) |
PRECAUTIONS
- General
.....Neutrexin
infusion should be permanently discontinued.....
|
|
|
Pamidronate Disodium
Injection
Pamidronate Disodium
for Injection
(click product name to read prescribing information) |
PRECAUTIONS
-
General
- Osteonecrosis of the
Jaw
- Musculoskeletal Pain
|
|
|
Parlodel
SnapTabs (bromocriptine mesylate) Tablets and Capsules
(click product name to read prescribing information)
|
PRECAUTIONS
- Hyperprolactinemic States
- Information for Patients
- Geriatric Use
ADVERSE REACTIONS
- Parkinson's Disease
- Pleural and
pericardial effusions, pleural, and pulmonary fibrosis
or retroperitoneal fibrosis.....
- Very rarely,
a syndrome resembling Neuroleptic Malignant Syndrome.....
|
|
|
PEG-Intron (peginterferon
alfa-2b) Powder for Injection
(click product name to read prescribing information) |
PRECAUTIONS
-
Drug Interactions
- Drugs Metabolized by Cytochrome P-450
|
|
|
Pletal
(cilostazol) Tablets
(click product name to read prescribing information) |
PRECAUTIONS
- Hepatic Impairment
- Renal Impairment
|
|
|
Revatio
(sildenafil citrate) Tablets
(click product name to read prescribing information)
|
PRECAUTIONS
ADVERSE REACTIONS
- When used
to treat male-erectile dysfunction, non-arteritic anterior
ischemic optic neuropathy (NAION), a
cause of decreased vision including permanent loss of
vision, has been reported rarely.....
|
|
|
Singulair
(montelukast
sodium) Tablets, Chewable Tablets, and Oral Granules
(click product name to read prescribing information)
|
PRECAUTIONS
ADVERSE REACTIONS
- Pediatric Patients 6 to 14
Years of Age with Asthma
PATIENT PACKAGE INSERT |
|
|
Valtrex
(valacyclovir hydrochloride) Caplets
(click product name to read prescribing information) |
PRECAUTIONS
-
Information for Patients
- Maintain Adequate Hydration
|
|
|
Zyvox (linezolid) Tablets and
Injection
Zyvox (linezolid) for Oral
Suspension
(click product name to read prescribing information) |
PRECAUTIONS |
MedWatch
Home | Safety Information | Submit
Report | How to Report | Download
Forms | Join the E-list | Comments
Back to Summary Page
MedWatch
Home | Safety Information | Submit
Report | How to Report | Download
Forms | Join the E-list | Comments
Back to Summary Page
|
|